# US 2020/0347408 A1 · Disrupting the linc complex for treating laminopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347408 A1
- Document ID: US20200347408A1
- Status: Published application
- Kind: A1
- Application number: 16/962,877
- Filed: 2019-01-18
- Published: 2020-11-05
- Earliest claimed: 2018-01-19
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Colin Lawson Stewart; Jinfen Chai; Yin Loon Lee; Brian Edmund Burke
- Web page: https://patentgrep.com/patent/US20200347408A1

## CPC

- C07K 14/47: from mammals
- C12N 15/86: Viral vectors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/502: {for testing non-proliferative effects}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0375: Animal model for cardiovascular diseases
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and/or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

## Claims

### Claim 1

A(n) isolated nucleic acid molecule, wherein the nucleic acid molecule comprises an expression vector and a transgene, whereby the transgene is operably linked to the expression vector, wherein expression of the transgene in a transfected cell results in disruption of a LInker of Nucleoskeleton and Cytoskeleton (LINC) complex in the transfected cell.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein the expression vector is a cardiac- or cardiomyocyte-specific expression vector.

### Claim 3 (depends on 1, 2)

The nucleic acid molecule of claim 1 or claim 2, wherein the expression vector comprises a cardiac- or cardiomyocyte-specific promoter.

### Claim 4 (depends on 3)

The nucleic acid molecule of claim 3, wherein the expression vector comprises a cardiac- or cardiomyocyte-specific promoter selected from the group comprising a cardiac troponin T promoter (cTnT), a α-myosin heavy chain (α-MHC) promoter and a myosin light chain (MLC2v) promoter.

### Claim 5 (depends on 3, 4)

The nucleic acid molecule of claim 3 or 4, wherein the cardiomyocyte-specific promoter is chicken cardiac troponin T (cTnT) promoter.

### Claim 6

The nucleic acid molecule of any one of the preceding claims, wherein the expression vector is a virus expression vector.

### Claim 7 (depends on 6)

The nucleic acid molecule of claim 6, wherein the virus expression vector is selected from the group comprising Lentivirus, Adenovirus and Adeno-associated virus (AAV).

### Claim 8

The nucleic acid molecule of any one of the preceding claims, wherein the adeno-associated virus expression vector (AAV) has cardiac tropism/is cardiotropic.

### Claim 9

The nucleic acid molecule of any one of the preceding claims, wherein in the AAV vector is selected from the group consisting of AAV9 (serotype 9), AAV1 (serotype 1), AAV6 (serotype 6), AAV8 (serotype 8), AAV28, and AAV9.45.

### Claim 10

The nucleic acid molecule of any one of the preceding claims, wherein in the AAV vector is AAV9 (serotype 9).

### Claim 11

The nucleic acid molecule of any one of the preceding claims, wherein transgene comprises nucleic acid sequences for expressing a lumenal domain of a SUN domain-containing protein, an N-terminal signal sequence, a signal peptidase cleavage site, and a C-terminal targeting peptide sequence.

### Claim 12 (depends on 11)

The nucleic acid molecule of claim 11, wherein the lumenal domain of the SUN domain-containing protein comprises a coiled coil domain and a SUN domain.

### Claim 13 (depends on 11)

The nucleic acid molecule of claim 11, wherein the coiled coil domain is upstream of the SUN domain.

### Claim 14

The nucleic acid molecule of any one of the preceding claims, wherein the transgene further comprises nucleic acid sequences for expressing an N-terminal signal sequence, a signal peptidase cleavage site, and a C-terminal targeting peptide sequence.

### Claim 15

The nucleic acid molecule of any one of the preceding claims, wherein the transgene comprises nucleic acid sequences for expressing an N-terminal signal sequence, a signal peptidase cleavage site, and a C-terminal targeting peptide sequence, and either the luminal domain of the SUN domain-containing protein or the SUN domain.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The nucleic acid molecule of any one of claims 11 to 15, wherein the SUN domain protein is SUN1 or SUN2.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The nucleic acid molecule of any one of claims 11 to 16, wherein the N-terminal signal sequence is derived from a secretory protein or a Type I transmembrane protein.

### Claim 18 (depends on 17)

The nucleic acid molecule of claim 17, wherein the secretory protein or Type I transmembrane protein is selected from the group consisting of human serum albumin, proinsulin, transferrin receptor, EGF receptor, pre-pro-opiomelanocortin, pancreatic digestive enzymes (for example, proteases, amylases and lipases), endoplasmic reticulum luminal proteins, for example protein disulphide isomerases, GRP94 and combinations thereof.

### Claim 19 (depends on 18)

The nucleic acid molecule of claim 18, wherein the N-terminal signal sequence is derived from human serum albumin.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The nucleic acid molecule of any one of claims 11 to 19, wherein the N-terminal signal sequence is not preceded at its N-terminus by any other tags.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The nucleic acid molecule of any one of claims 11 to 20, wherein the signal peptidase cleavage site is a signal peptidase cleavage site derived from or is one of the group consisting of human serum albumin, proinsulin, transferrin receptor, EGF receptor, pre-pro-opiomelanocortin, pancreatic digestive enzymes (for example, proteases, amylases and lipases), endoplasmic reticulum lumenal proteins, such as protein disulphide isomerases, GRP94 and combinations thereof.

### Claim 22 (depends on 21)

The nucleic acid molecule of claim 21, wherein the signal peptidase cleavage site is a signal peptidase cleavage site derived from human serum albumin.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The nucleic acid molecule of any one of claims 11 to 22, wherein the C-terminal targeting peptide sequence prevents secretion of a peptide expressed from the transgene according to any one of claims 1 to 19.

### Claim 24 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The nucleic acid molecule of any one of claims 11 to 23, wherein the C-terminal targeting peptide sequence is a KDEL sequence.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The nucleic acid molecule of any one of claims 1 to 24, wherein the transgene further comprises an epitope tag.

### Claim 26 (depends on 25)

The nucleic add molecule of claim 25, wherein the optional epitope tag Is N-terminal, or located anywhere in the nucleic acid molecule except downstream of (after) the C-terminal targeting peptide sequence [for example KDEL], or located anywhere in the nucleic acid molecule except upstream of (before) the N-terminal signal sequence.

### Claim 27 (depends on 26)

The nucleic add molecule of claim 26, wherein the optional epitope tag Is selected from the group consisting of cellulose binding domain (CBD), chloramphenicol acetyl transferase (CAT), dihydrofolate reductase (DHFR), one or more FLAG tags, glutathione S-transferase (GST), green fluorescent protein (GFP), haemagglutinin A (HA), histidine (His), Herpes simplex virus (HSV), luciferase, maltose-binding protein (MBP), c-Myc, Protein A, Protein G, streptavidin, T7, thioredoxin, V5, vesicular stomatitis virus glycoprotein (VSV-G), and combinations thereof.

### Claim 28 (depends on 27)

The nucleic acid molecule of claim 27, wherein the epitope tag is haemagglutinin A (HA).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The nucleic acid molecule of any one of the preceding claims, wherein the vector is the adeno-associated virus vector (AAV) comprising the chicken cardiac troponin T promoter (cTnT), and the transgene according to any one of claims 1 to 28, wherein the luminal domain of the SUN domain-containing protein is derived from SUN1, wherein the N-terminal signal sequence and the signal peptidase cleavage site are each derived from human serum albumin, wherein the C-terminal targeting peptide sequence is the KDEL sequence, and wherein the transgene further comprises haemagglutinin (HA) as the N-terminal epitope tag.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The nucleic acid molecule of any one of the preceding claims, wherein the vector is the adeno-associated virus vector (AAV) comprising the chicken cardiac troponin T promoter (cTnT), and the transgene according to any one of claims 1 to 28, wherein the luminal domain of the SUN domain-containing protein is derived from SUN2, wherein the an N-terminal signal sequence and the signal peptidase cleavage site are each derived from human serum albumin, and wherein the C-terminal targeting peptide sequence is the KDEL sequence, and wherein the transgene further comprises haemagglutinin (HA) as the N-terminal epitope tag.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid molecule of any one of claims 1 to 10, wherein the transgene comprises nucleic acid sequences for expressing a KASH domain, and an N-terminal stabiliser polypeptide sequence.

### Claim 32 (depends on 31)

The nucleic acid molecule of claim 31, wherein the KASH domain comprises a transmembrane domain and a SUN-interacting peptide.

### Claim 33 (depends on 31, 32)

The nucleic acid molecule of any one of claims 31 to 32, wherein the KASH domain is selected from the group consisting of KASH1 (derived from Nesprin-1 (SYNE1 gene)), KASH2 (derived from Nesprin-2 (SYNE2 gene)), KASH3 (derived from Nesprin-3 (SYNE3 gene)), KASH4 (derived from Nesprin-4 (SYNE4 gene)), and KASH5 (derived from KASH5/CCDC155 (KASH5 gene)).

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid molecule of any one of claims 1 to 10, wherein the transgene comprises nucleic acid sequences for expressing a CRISPR-Cas or other synthetic nuclease system to modify nucleic acid that encodes the SUN domain or KASH domain of endogenous Sun or Nesprin protein, respectively.

### Claim 35 (depends on 34)

The nucleic acid molecule of claim 34, wherein the transgene comprises nucleic acid sequences for expressing a CRISPR-Cas.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The nucleic acid molecule of any one of claims 1 to 33, wherein the transgene is a dominant negative construct.

### Claim 37

The nucleic acid molecule of any one of the preceding claims, wherein the transgene is a humanised or human transgene.

### Claim 38

The nucleic acid molecule of any one of the preceding claims, wherein expression of the transgene results in the disruption of the protein-protein interaction between SUN and KASH of the LINC complex.

### Claim 39 (depends on 38)

The nucleic acid molecule of claim 38, wherein the disruption of the protein-protein interaction between SUN and KASH of the LINC complex occurs between the protein interactions selected from the group consisting of Sun1+Nesprin-1, Sun2+Nesprin-1, Sun1+Nesprin-2, Sun1+Nesprin-3, Sun2+Nesprin-2, and Sun2+Nesprin-3.

### Claim 40 (depends on 39)

The nucleic acid molecule of claim 39, wherein the disruption of the protein-protein interaction between SUN and KASH of the LINC complex occurs between Sun1 and Nesprin-1.

### Claim 41

The nucleic acid molecule of any one of the preceding claims, wherein the AAV vector is formulated for delivery into the myocardium of a subject.

### Claim 42

The nucleic acid molecule of any one of the preceding claims for use in treating a disease caused by one or more Lmna mutations in a subject.

### Claim 43 (depends on 42)

The nucleic acid molecule of claim 42, wherein the disease is selected from the group consisting of restrictive dermopathy, familial partial lipodystrophy (for example, Dunnigan type), mandibuloacral dysplasia with type A lipodystrophy, metabolic syndrome, Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2B1 and diseases presented in normal font in Table 1.

### Claim 44

The nucleic acid molecule of any one of the preceding claims for use in treating cardiovascular disease in a subject.

### Claim 45 (depends on 42, 43)

The nucleic acid molecule of claim 42 or 43, wherein the disease or the cardiovascular disease is characterised by the presence of at least one Lmna mutation.

### Claim 46 (depends on 44, 45)

The nucleic acid molecule of any one of claims 44 to 45, wherein the cardiovascular disease is selected from the group consisting of laminopathy, cardiomyopathy, such as dilated cardiomyopathy (DCM), dilated cardiomyopathy 1A, dilated cardiomyopathy with conduction system defects, cardiomyopathy with advanced AV block and arrhythmia, lone atrial fibrillation; muscular dystrophy (often associated with cardiomyopathy), such as cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal dominant), cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal recessive), cardiomyopathy associated with Limb-girdle muscular dystrophy type 1B, cardiomyopathy associated with congenital muscular dystrophy; premature aging syndromes (thought to be primarily vascular, but may have cardiac involvement) such as cardiomyopathy associated with Atypical Werner syndrome, cardiomyopathy associated with Hutchinson-Gilford progeria syndrome and the like, as well as diseases presented in bold font in Table 1.

### Claim 47 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 34, 35, 36, 37, 38)

An adeno-associated virus vector (AAV) comprising the cardiac troponin T promoter (cTnT), and the transgene according to any one of claims 11 to 30 or claims 34 to 38.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

A pharmaceutical composition comprising the nucleic acid molecule according to any one of claims 1 to 41.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 48)

A method of treating a disease in a subject, the method comprising administration of a pharmaceutically effective amount of the nucleic acid molecule according to any one of claims 1 to 41, or the pharmaceutical composition of claim 48.

### Claim 50 (depends on 49)

The method of claim 49, wherein the disease is characterised by the presence of at least one Lmna mutation.

### Claim 51 (depends on 49, 50)

The method of any one of claims 49 to 50, wherein the Lmna mutation(s) affect(s) lamin A isoform, or lamin C isoform of the Lmna gene, or both lamin A/C isoforms.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the disease is selected from the group consisting of restrictive dermopathy, familial partial lipodystrophy (for example, Dunnigan type), mandibuloacral dysplasia with type A lipodystrophy, metabolic syndrome, Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2B1 and diseases present in normal font in Table 1.

### Claim 53 (depends on 49, 50, 51)

The method according to any one of claims 49 to 51, wherein the disease is a cardiovascular disease selected from the group consisting of laminopathy, cardiomyopathy, such as dilated cardiomyopathy (DCM), dilated cardiomyopathy 1A, dilated cardiomyopathy with conduction system defects, cardiomyopathy with advanced AV block and arrhythmia, lone atrial fibrillation; muscular dystrophy (often associated with cardiomyopathy), such as cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal dominant), cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal recessive), cardiomyopathy associated with Limb-girdle muscular dystrophy type 1B, cardiomyopathy associated with congenital muscular dystrophy; premature aging syndromes (thought to be primarily vascular, but may have cardiac involvement) such as cardiomyopathy associated with Atypical Werner syndrome, cardiomyopathy associated with Hutchinson-Gilford progeria syndrome; and diseases presented in bold font in Table 1.

### Claim 54 (depends on 49, 50, 51, 52, 53)

The method of any one of claims 49 to 53, wherein the subject is a non-human mammal or a human.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 48)

Use of the pharmaceutical composition according to claim 48 or the nucleic acid molecule according to any one of claims 1 to 41 in the manufacture of a medicament for treating a disease caused by one or more Lmna mutations or cardiovascular disease.

### Claim 56 (depends on 55)

The use of claim 55, wherein the disease is selected from the group consisting of restrictive dermopathy, familial partial lipodystrophy (for example, Dunnigan type), mandibuloacral dysplasia with type A lipodystrophy, metabolic syndrome, Charcot-Marie-Tooth disease type 2, Charcot-Marie-Tooth disease type 2B1 and diseases presented in normal font in Table 1.

### Claim 57 (depends on 55)

The use of claim 55, wherein the cardiovascular disease is selected from the group consisting of laminopathy, cardiomyopathy, such as dilated cardiomyopathy (DCM), dilated cardiomyopathy 1A, dilated cardiomyopathy with conduction system defects, cardiomyopathy with advanced AV block and arrhythmia, lone atrial fibrillation; muscular dystrophy (often associated with cardiomyopathy), such as cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal dominant), cardiomyopathy associated with Emery-Dreifuss muscular dystrophy (autosomal recessive), cardiomyopathy associated with Limb-girdle muscular dystrophy type 1B, cardiomyopathy associated with congenital muscular dystrophy; premature aging syndromes (thought to be primarily vascular, but may have cardiac involvement) such as cardiomyopathy associated with Atypical Werner syndrome, cardiomyopathy associated with Hutchinson-Gilford progeria syndrome and the like, as well as diseases presented in bold font in Table 1.

### Claim 58 (depends on 48)

The pharmaceutical composition according to claim 48 for use in therapy.

### Claim 59

A method of screening for drug candidates capable of inhibiting the interaction of the proteins of a LINC complex in a cell, which comprises:
(a) combining the proteins of said LINC complex in the presence of a drug to form a first complex;
(b) combining the proteins in the absence of said drug to form a second complex;
(c) measuring the amount of said first complex and said second complex; and
(d) comparing the amount of said first complex with the amount of said second complex,
wherein if the amount of said first complex is less than the amount of said second complex, then the drug is a drug candidate for inhibiting the interaction of the proteins of said LINC complex in a cell.

### Claim 60 (depends on 59)

The method of claim 59, wherein the drug candidate disrupts the protein-protein interaction between SUN and KASH of the LINC complex.

### Claim 61 (depends on 60)

The method of claim 60, wherein the drug candidate disrupts the interaction between Sun1 and Nesprin-1 proteins.

### Claim 62 (depends on 59, 60, 61)

The method of any one of claims 59 to 61, wherein the screening is an in vitro screening.

### Claim 63 (depends on 59, 60, 61, 62)

The method of any one of claims 59 to 62, wherein the complex is measured by an ELISA method or by a fluorescence anisotropy method.

### Claim 64 (depends on 59, 60, 61, 62, 63)

The method of any one of claims 59 to 63, wherein if the amount of said first complex is less than the amount of said second complex, then said drug is a drug candidate for inhibiting the interaction of said proteins.

### Claim 65 (depends on 59, 60, 61, 62, 63, 64)

The method of any one of claims 59 to 64, wherein recombinant SUN and KASH domains are used.
